Highly sensitive determination of C-reactive protein on the Innotrac Aio! immunoanalyzer

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 64, Issue 7, 2004, Pages 677-686

  Hedberg, Pirjo ^a   Ylitalo, K ^a   Puukka, M ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Analytic performance; Point of care; Risk assessment; usCRP

Indexed keywords

C REACTIVE PROTEIN; EDETIC ACID; HEPARIN; LITHIUM;

ARTICLE; ATHEROMA; AUTOANALYSIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; IMMUNOASSAY; INFLAMMATION; LABORATORY AUTOMATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 7044271087     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510410002931     Document Type: Article

References (10)

1. Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
2. Ridker P, Rifai N, Clearfield M, Downs J, Weis S, Miles J. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.
3. Ridker P, Cushman M, Spampfer M, Tracy R, Hennekens C. Plasma concentration C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-8.
4. Ridker P, Hennekens C, Buring J, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
5. Koenic W, Sund M, Fröhlich M, Fischer Hhyphen G, Löwel H, Döring A, Hutchinson W, Pepys M. C-reactiveprotein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999; 99: 237-42.
6. Ledue T, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 2003; 49: 1258-71.
7. Pearson T, Mensah G, Alexander R, Anderson J, Cannon III R, Cricqui M, Fadl Y, Fortman S, Hong Y, Myers G, Rifai N, Smith S, Taubert K, Tracy R, Vinicor F. AHA/CDC Scientific Statement. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for Healthcare professionals from the centers for disease control and prevention and the American Association. Circulation 2003; 107: 499-511.
8. Hedberg P, Puukka M. Highly sensitive determination of C-reactive protein on the Innotrac Aio! immunoanalyzer. Clin Chem Lab Med 2003; 41 Suppl. W-126: S426.
9. Roberts W, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 2000; 46: 461-8.
10. Roberts W, Moulton L, Law T, Farrow G, Cooper-Anderson M, Savory J, Rifai N. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001; 47: 418-25.